Predict toxicity before it occurs?
Thursday, Nov. 10, FDA Grand Rounds
12:00-1:00 p.m. EST
About the Presentation
FDA's Dr. Richard Beger, internationally recognized leader in toxicology
and winner of the prestigious Society of Toxicology Translational Impact
Award,will discuss how metabolomics and proteomics technologies are
being used in nonclinical and clinical studies to discover translational
biomarkers in biofluids that would enable us to diagnose toxicity and
predict toxicity before it occurs.
His presentation will discuss the discovery of metabolomics and proteomics
biomarkers following administration of acetaminophen in mice, rats, and
children. Another study will explore biomarkers of doxorubicin cardiotoxicity.
Sept 8 FDA Grand Rounds Now Available on Webcast
Due to system-wide technical difficulties, FDA's Sept. 8 Grand Rounds could not be viewed in its entirety. We are pleased to announce that Dr. Connie M. Ruzicka's entire presentation on Rapid Screening of Dietary Supplements for Undeclared Ingredients is now available for viewing.
Dr. Ruzicka presents on a rapid, reliable screening tool FDA's Center for Drug Evaluation and Research has developed called ion mobility spectrometry (IMS) for product quality surveillance and FDA efforts to deploy the IMS instruments in the field for on-site testing. IMS screening can quickly identify violative products and help FDA to remove these products from the marketplace.